Revance Therapeutics Investor Presentation — January 2020

Document content

38thAnnual JP Morgan Healthcare Conference

Company Presentation

January 16, 2020Forward -Looking Statements / Safe Harbor / Market Data

This presentation contains forward -looking statements, including forward -statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics, the

process and timing of, and ability to complete, current and anticipated future clinical development of our investigational pr odu ct candidates, including anticipated near -term milestones; the initiation, enrollment,

design, timing and outcome of our clinical trials, including for the treatment of glabellar (frown) lines, forehead lines, la teral canthal lines (crow’s feet), cervical dystonia, plantar fasciitis, adult upper limb spasticity

and chronic migraine, relating to DaxibotulinumtoxinA for Injection (DAXI); and related results and reporting of such results and statements; timing and outcome of regulatory determinations regarding the potential

label for DAXI to treat glabellar (frown) lines and commercial potential of our drug candidates; anticipated strategic and fi nan cial benefits of our distribution agreement with Teoxane; commercial acceptance and

potential of Teoxane’s dermal fillers, including market size and anticipated adoption rates; status of commercial collaborati ons , including collaboration agreement with Mylan’s continuation decision and the timing

thereof; our ability to obtain, and timing relating to, regulatory approval with respect to our drug candidates; our ability to commercialize and launch, and related timelines relating to, our product candidates; the

potential aesthetic, therapeutic and economic benefits and value of our product candidates and our technologies; demand for o ur product candidates and drivers of demand; market size, adoption rate and potential

revenue; growth opportunities and product pipeline; our business strategy, timeline and other goals and market for our antici pated products, plans and prospects; our ability to leverage our investment in our

development and manufacturing platform; our commercial and intellectual property strategy; and our financial and operating pr ojections, including cash and operating expense forecast.

Forward -looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome,

cost and timing of our product development activities and clinical trials; the uncertain clinical development process, includ ing the risk that clinical trials may not have an effective design or generate positive results, or

that positive results would assure regulatory approval or commercial success of our product candidates; that we may not obtai n the anticipated financial and other benefits of the collaboration agreement with Mylan